{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:42:14Z","timestamp":1774993334221,"version":"3.50.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0238262","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T17:26:57Z","timestamp":1599240417000},"page":"e0238262","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-9578","authenticated-orcid":true,"given":"Alexander","family":"Philipovskiy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok K.","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeina","family":"Nahleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato J.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"pone.0238262.ref001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"CE DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"pone.0238262.ref002","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"BD Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"pone.0238262.ref003","doi-asserted-by":"crossref","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection","volume":"11","author":"BD Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"pone.0238262.ref004","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"H Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"pone.0238262.ref005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-negative breast cancer: role of specific chemotherapy agents","volume":"16","author":"SJ Isakoff","year":"2010","journal-title":"Cancer J"},{"key":"pone.0238262.ref006","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Y Shi","year":"2018","journal-title":"Mol Cancer"},{"key":"pone.0238262.ref007","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","article-title":"Genetic markers in triple-negative breast cancer","volume":"18","author":"Z Sporikova","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"pone.0238262.ref008","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.21873\/invivo.11594","article-title":"Efficacy of neoadjuvant versus adjuvant chemotherapy in Hispanic\/Latino (H\/L) women with local or locally advanced triple-negative breast cancer (TNBC)","volume":"33","author":"A Philipovskiy","year":"2019","journal-title":"In Vivo"},{"key":"pone.0238262.ref009","doi-asserted-by":"crossref","first-page":"14863","DOI":"10.1038\/s41598-019-51335-1","article-title":"A predictor of pathological complete response to neoadjuvant chemotherapy stratifies triple-negative breast cancer patients with high risk of recurrence","volume":"9","author":"MV Fournier","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0238262.ref010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2014.17322","article-title":"Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States","volume":"313","author":"J Iqbal","year":"2015","journal-title":"JAMA"},{"key":"pone.0238262.ref011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"RL Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"pone.0238262.ref012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1055-9965.EPI-17-0420","article-title":"Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution","volume":"27","author":"SJ Serrano-Gomez","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"pone.0238262.ref013","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1002\/cncr.25961","article-title":"Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity","volume":"117","author":"F Lara-Medina","year":"2011","journal-title":"Cancer"},{"key":"pone.0238262.ref014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/carcin\/bgw043","article-title":"High prevalence of luminal B breast cancer intrinsic subtype in Colombian women","volume":"37","author":"SJ Serrano-Gomez","year":"2016","journal-title":"Carcinogenesis"},{"key":"pone.0238262.ref015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3816\/CBC.2010.n.038","article-title":"Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database","volume":"10","author":"CS Vallejos","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"pone.0238262.ref016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.21873\/anticanres.14018","article-title":"Adherence to adjuvant aromatase inhibitor therapy among postmenopausal Hispanic\/Latino women with breast cancer","volume":"40","author":"A Philipovskiy","year":"2020","journal-title":"Anticancer Res"},{"key":"pone.0238262.ref017","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies","volume":"35","author":"YZ Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"pone.0238262.ref018","doi-asserted-by":"crossref","first-page":"e6501","DOI":"10.7717\/peerj.6501","article-title":"Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene","volume":"7","author":"S Niyomnaitham","year":"2019","journal-title":"PeerJ"},{"key":"pone.0238262.ref019","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"B Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"pone.0238262.ref020","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","volume":"12","author":"M Olivier","year":"2006","journal-title":"Clin Cancer Res"},{"key":"pone.0238262.ref021","doi-asserted-by":"crossref","first-page":"624","DOI":"10.18632\/oncotarget.13483","article-title":"TP53 mutations, expression and interaction networks in human cancers","volume":"8","author":"X Wang","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0238262.ref022","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001677","article-title":"Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events","volume":"3","author":"T Meissner","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"pone.0238262.ref023","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156652406779010830","article-title":"Notch signaling in cancer","volume":"6","author":"L Miele","year":"2006","journal-title":"Curr Mol Med"},{"key":"pone.0238262.ref024","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fonc.2018.00518","article-title":"Moving breast cancer therapy up a Notch","volume":"8","author":"EWJ Mollen","year":"2018","journal-title":"Front Oncol"},{"key":"pone.0238262.ref025","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","article-title":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor","volume":"21","author":"K Wang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"pone.0238262.ref026","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cge.13382","article-title":"Overlapping but distinct roles for NOTCH receptors in human cardiovascular disease","volume":"95","author":"JAN Meester","year":"2019","journal-title":"Clin Genet"},{"key":"pone.0238262.ref027","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment","volume":"9","author":"AC Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"pone.0238262.ref028","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cncr.28914","article-title":"Subtyping of triple-negative breast cancer: implications for therapy","volume":"121","author":"VG Abramson","year":"2015","journal-title":"Cancer"},{"key":"pone.0238262.ref029","first-page":"3581","article-title":"Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico","volume":"17","author":"GI Uscanga-Perales","year":"2019","journal-title":"Oncol Lett"},{"key":"pone.0238262.ref030","article-title":"Revealing the Molecular Portrait of triple-negative breast tumors in an understudied population through omics analysis of formalin-fixed and paraffin\u2014embedded tissue","author":"F Vaca-Paniagua","year":"2015","journal-title":"PLOS one"},{"key":"pone.0238262.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246197","article-title":"Gain-of-function mutant p53: All the roads lead to tumorigenesis","volume":"20","author":"Y Stein","year":"2019","journal-title":"Int J Mol Sci"},{"key":"pone.0238262.ref032","doi-asserted-by":"crossref","first-page":"698","DOI":"10.21037\/tcr.2016.11.74","article-title":"Pharmacological targeting of mutant p53","volume":"5","author":"S Kogan","year":"2016","journal-title":"Transl Cancer Res"},{"key":"pone.0238262.ref033","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.febslet.2014.04.017","article-title":"Mutant p53 reactivation by small molecules makes its way to the clinic","volume":"588","author":"VJ Bykov","year":"2014","journal-title":"FEBS Lett"},{"key":"pone.0238262.ref034","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fphar.2019.00864","article-title":"Wee1 inhibitor AZD1775 effectively inhibits the malignant phenotypes of esophageal squamous cell carcinoma in vitro and in vivo","volume":"10","author":"S Bi","year":"2019","journal-title":"Front Pharmacol"},{"key":"pone.0238262.ref035","doi-asserted-by":"crossref","first-page":"e0191766","DOI":"10.1371\/journal.pone.0191766","article-title":"Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines","volume":"13","author":"S Maleki Vareki","year":"2018","journal-title":"PLoS One"},{"key":"pone.0238262.ref036","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/375736a0","article-title":"Developmental genetics. The Notch connection","volume":"375","author":"P Simpson","year":"1995","journal-title":"Nature"},{"key":"pone.0238262.ref037","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-009-8668-7","article-title":"The Notch signaling pathway: transcriptional regulation at Notch target genes","volume":"66","author":"T Borggrefe","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"pone.0238262.ref038","article-title":"Notch signaling pathway in pancreatic cancer progression","volume":"3","author":"J Ma","year":"2013","journal-title":"Pancreat Disord Ther"},{"key":"pone.0238262.ref039","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/14737140.8.8.1197","article-title":"Rational targeting of Notch signaling in breast cancer","volume":"8","author":"L Miele","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"pone.0238262.ref040","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-05-3054","article-title":"Aberrant activation of notch signaling in human breast cancer","volume":"66","author":"S Stylianou","year":"2006","journal-title":"Cancer Res"},{"key":"pone.0238262.ref041","first-page":"197","article-title":"Role of Notch and its oncogenic signaling crosstalk in breast cancer","volume":"1815","author":"S Guo","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"pone.0238262.ref042","doi-asserted-by":"crossref","first-page":"e0131689","DOI":"10.1371\/journal.pone.0131689","article-title":"Expression of Notch1 correlates with breast cancer progression and prognosis","volume":"10","author":"X Yuan","year":"2015","journal-title":"PLoS One"},{"key":"pone.0238262.ref043","first-page":"8749","article-title":"The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer","volume":"15","author":"JW Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"pone.0238262.ref044","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors","volume":"35","author":"R Ferrarotto","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0238262.ref045","doi-asserted-by":"crossref","first-page":"a000539","DOI":"10.1101\/mcs.a000539","article-title":"Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the gamma-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case","volume":"1","author":"B Knoechel","year":"2015","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"pone.0238262.ref046","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acsmedchemlett.5b00001","article-title":"Discovery of clinical candidate BMS-906024: A potent pan-Notch inhibitor for the treatment of leukemia and solid tumors","volume":"6","author":"AV Gavai","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"pone.0238262.ref047","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.18632\/oncotarget.13727","article-title":"Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer","volume":"8","author":"MA Locatelli","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0238262.ref048","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-11-3326","article-title":"Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors","volume":"19","author":"AF Schott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"pone.0238262.ref049","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"MJ Ellis","year":"2012","journal-title":"Nature"},{"key":"pone.0238262.ref050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/mc.22538","article-title":"Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK","volume":"56","author":"M Zhao","year":"2017","journal-title":"Mol Carcinog"},{"key":"pone.0238262.ref051","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41422-018-0044-4","article-title":"MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models","volume":"28","author":"Z Xue","year":"2018","journal-title":"Cell Res"},{"key":"pone.0238262.ref052","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"J Pascual","year":"2019","journal-title":"Ann Oncol"},{"key":"pone.0238262.ref053","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.advenzreg.2009.10.015","article-title":"Indirect mechanisms of carcinogenesis via downregulation of PTEN function","volume":"50","author":"NR Leslie","year":"2010","journal-title":"Adv Enzyme Regul"},{"key":"pone.0238262.ref054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-010-1108-4","article-title":"Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy","volume":"124","author":"CM Coughlin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0238262.ref055","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"J Li","year":"1997","journal-title":"Science"},{"key":"pone.0238262.ref056","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-07-4864","article-title":"Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas","volume":"14","author":"T Palomero","year":"2008","journal-title":"Clin Cancer Res"},{"key":"pone.0238262.ref057","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010121","article-title":"The oncogene addiction switch from NOTCH to PI3K requires simultaneous targeting of NOTCH and PI3K pathway inhibition in glioblastoma","volume":"11","author":"N Saito","year":"2019","journal-title":"Cancers (Basel)"},{"key":"pone.0238262.ref058","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"SB Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"pone.0238262.ref059","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial","volume":"38","author":"P Schmid","year":"2020","journal-title":"J Clin Oncol"},{"key":"pone.0238262.ref060","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"F Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"pone.0238262.ref061","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"J Baselga","year":"2017","journal-title":"Lancet Oncol"},{"key":"pone.0238262.ref062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"M Martin","year":"2017","journal-title":"Ann Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T17:27:20Z","timestamp":1599240440000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238262"}},"subtitle":[],"editor":[{"given":"Nandini","family":"Dey","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0238262","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}